Tweet
Pete Meenen and the Tennesseans We Lost to COVID-19
The state’s first resident claimed by a virus that went on to kill many more
On March 21, the Brentwood Family YMCA shared the news that Pete Meenen, a greeter at the gym and community center for more than 20 years, had died. He was the first person in Tennessee to die from COVID-19.
“Perhaps few faces in a YMCA are as recognizable as the greeter who meets the morning faithful, the early risers who start their day with us when the Welcome Center is a little quieter than usual,” the Brentwood Y’s operations executive, Roger D. Grove, wrote on Facebook. “For more than 20 years, Pete was that face in our YMCA, and his loss will be deeply felt by all of us, our staff and our members.”
New Montefiore Study Demonstrates How Doctors & Caregivers Can Partner To Improve Children s Care At Home After Hospitalization
USA - English
News provided by
Share this article
Share this article
NEW YORK, Jan. 6, 2021 /PRNewswire/ Many children need to take medication at home after being discharged from the hospital. Recent research conducted at the Children s Hospital at Montefiore (CHAM) and Albert Einstein College of Medicine found that 70 percent of caregivers either mismanage or don t fully understand hospital discharge medication instructions, leading to problems such as wrong dosage or confusion about side effects. Now, the same CHAM investigators looked at ways to correct this issue and published their results in
Myeloid Therapeutics Launches with Over $50 Million in Financing and Two Clinical Trials
Myeloid s cell therapy harnesses the innate capabilities of myeloid lineage cells to fight cancer
Scientific founders include world-renowned cell therapy & cancer experts Ronald Vale, Ph.D. and Siddhartha Mukherjee, M.D., D.Phil.
Co-Founded by Thomas Cahill, M.D., Ph.D., with financing led by Newpath Partners and participation from leading biotech investors
News provided by
Share this article
Share this article
CAMBRIDGE, Mass., Jan. 6, 2021 /PRNewswire/ Myeloid Therapeutics, Inc., a company harnessing and reprogramming myeloid cells for treating cancers, launched today with over $50 million in financing to initiate multiple clinical trials in 2021. The Company combines advanced gene and cell engineering capabilities with substantial biologics knowledge to elucidate and redirect the power of myeloid cells to treat cancers, particularly solid tumors and those that are poorly served by exi
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Study of patients undergoing abdominal aortic aneurysm repair suggests screening guidelines may .
Society for Vascular SurgeryJanuary 5, 2021 GMT
Rosemont, Ill., Jan. 05, 2021 (GLOBE NEWSWIRE) A retrospective study analyzing approximately 55,000 patients undergoing abdominal aortic aneurysm (AAA) repair suggests current AAA screening guidelines may be inadequate in detecting a significant number of new cases. Additionally, expanding screening for certain population segments may be warranted. The study patients were enrolled in the Vascular Quality Initiative between years 2003 and 2019.
The study was spearheaded by Jeffrey E. Indes, MD, vascular surgeon at Montefiore Einstein Center for Heart and Vascular Care, and results were published in the December 2020 edition of the Journal of Vascular Surgery.
Credit: RLT Images
While most scientists look at Covid-19 as a viral respiratory illness, Nir Barzilai takes a slightly different perspective. Instead Barzilai, founder of the Institute of Ageing Research at the Albert Einstein College of Medicine in New York, sees it as a disease of ageing.
The grim statistics show that he has a point. In Europe, people over 60 have accounted for 90% of fatalities since the start of August. While the impact of Covid-19 has been universal, older people have been disproportionally affected.
“This virus has no eyes, but it could see immediately who is old and more vulnerable,” says Barzilai.